Abiopharma

🔍 Busch Matthew C. (Executive)

Company: AMGEN INC (AMGN)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Sold 41 shares of Common Stock at $331.11 per share (Direct)
  Date: 2026-05-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 4,344.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: These shares include 39 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.